C R Bard Inc (BCR.N)
* Priced public offering of 10-year senior notes in aggregate principal amount of $500 million and with interest rate of 3% per year Source (http://bit.ly/1OeKDKZ) Further company coverage:
* Says coo john weiland's fy 2015 total compensation $6.9 million versus $7.0 million in fy 2014
A federal appeals court has rejected a request from four plaintiffs suing C.R. Bard over transvaginal mesh to let their cases leave the West Virginia court where they have been consolidated with thousands of similar claims in multidistrict litigation.
A Missouri jury has cleared medical device manufacturers Boston Scientific and C.R. Bard of liability in the first trial involving a woman who said she was injured by transvaginal mesh devices made by more than one company.
|Johnson & Johnson (JNJ.N)||$124.78||-0.11|
|Abbott Laboratories (ABT.N)||$43.53||+0.12|
|Covidien Ltd (COV.N)||--||--|
|Becton Dickinson and Co (BDX.N)||$174.38||+1.60|
|Boston Scientific Corporation (BSX.N)||$23.85||+0.15|
|St. Jude Medical, Inc. (STJ.N)||$82.09||+0.08|
|Teleflex Incorporated (TFX.N)||$176.97||+0.82|
|AngioDynamics, Inc. (ANGO.OQ)||$16.67||+0.18|
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Trading Report for (BCR). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Wright Reports
"The Economy Matters" Report for BCR: the economy's impact on BCR's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider : MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.